Navigation Links
Rigel Announces Participation at Two Investor Conferences
Date:2/9/2011

SOUTH SAN FRANCISCO, Calif., Feb. 9, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to participate at two investor conferences in New York City next week. Details of the events are as follows:Tuesday, February 15 at 9:00 a.m. ET13th Annual BIO CEO & Investor ConferencePanel Topic:  "Rheumatoid Arthritis: the Real Joint Problem"Tuesday, February 15 at 3:30 p.m. ET13th Annual BIO CEO & Investor ConferenceRigel Company Presentation (webcast)Thursday, February 17 at 7:45 a.m. ETLeerink Swann Hot Topics in Therapeutics Roundtable ConferencePanel Topic:  "Rheumatology"The company presentation at BIO CEO will be webcast live and can be accessed at www.rigel.com.  Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for RA (partnered with AstraZeneca), and R343, an inhaled syk inhibitor that is in clinical trials for asthma (partnered with Pfizer).

Contact: Ryan MaynardPhone: 650.624.1284Email:

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Research and Markets  has ... Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, ... http://photos.prnewswire.com/prnh/20130307/600769 ... category in IVD testing with competitive participation by ... employers, criminal justice personnel, and sports use drug ...
(Date:8/1/2014)... 1, 2014  VanDeMark Chemical Inc., ... of phosgene and phosgene derivatives in ... has acquired Framochem Kft, a leading European-based manufacturer ... . The purchase unites two ... of the world,s largest, independent manufacturers of products ...
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable ... focused exclusively on the healthcare industry, announced today ... The Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway ... and supplies technologies to customers in the global ... transaction were not disclosed. Vesta is ...
Breaking Medicine Technology:Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) 2VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2
(Date:8/1/2014)... York (PRWEB) August 01, 2014 Parker ... the rights of victims injured by defective medical devices ... would be recalling its Ethicon surgical power morcellator devices ... maker sited concerns involving the spread of cancer associated ... report dated July 31, 2014. , Johnson & ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 01, 2014 The American Telemedicine ... Harper (R-MS), and Peter Welch (D-VT), for their ... Telehealth Parity Act of 2014, which improves telemedicine ... effort to improve healthcare access and affordability using ... of ATA. "These cost-saving provisions are critical to ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... at the Massachusetts Institute of Technology (MIT) has found ... ability to deform, and squeeze through tiny blood vessels ... the malaria-inducing parasite Plasmodium falciparum. ,The ... called RESA (ring-infected erythrocyte surface antigen), and found that ...
... the capital on Saturday. ,The Nigah Queer ... by many international directors. The films will be followed by ... of the programme is to give voice to the issue ... Code (IPC) is still in existence. Section 377 criminalizes private ...
... It seems that Hollywood hunk Brad Pitt is enjoying parental bliss ... the pregnant Myleene Klass at Cannes, Pitt poured his heart out ... have had your first scan yet? They're mind-blowing. Get ready to ... - it's the best thing that ever happened to me,' the ...
... new scare over soft drinks is in the making following revelations ... and Pepsi Max has the ability to switch off vital ... ,For when parts of DNA are disabled, as it were, it ... such as Parkinson's. ,Concerns centre on the safety of ...
... largest ever Parkinson's disease (PD) clinical trials to determine ... symptom progression of this disorder. ,PD is ... develop tremor, slowness of movements and stiffness of muscles. ... U.S. Currently, there are a number of effective treatments ...
... the way of administering the one effective drug, the ... in the USA, reports say . ,Stroke ... behind heart disease and cancer, killing 150,000 Americans a ... nation $62.7 billion, according to the American Stroke Association. ...
Cached Medicine News:Health News:Why Malaria Parasite Affects Red Blood Cells Deformability Revealed 2Health News:Gay Film Festival Begins in Delhi 2Health News:Soft Drink Additive Could Cause Cell Damage 2Health News:Soft Drink Additive Could Cause Cell Damage 3Health News:Emory Participates in Study to Slow Progression of Parkinson's Disease 2Health News:Lack of Timely Intervention Results in Needless Death Due to Stroke in US 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
The Intradyn Tear-Away Introducer Sheath with Spin-Lock offers a secure dilatorsheath connection, a smooth dilatorsheath transition and a clean, even tear....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Medicine Products: